Cargando…

Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries

OBJECTIVES: Burden of comorbidities are largely unknown in JIA. From 2000, national and international patient registries were established to monitor biologic treatment, disease activity and adverse events in patients with JIA. The aim of this analysis was to investigate in parallel, for the first ti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kearsley-Fleet, Lianne, Klotsche, Jens, van Straalen, Joeri W, Costello, Wendy, D’Angelo, Gianfranco, Giancane, Gabriella, Horneff, Gerd, Klein, Ariane, Láday, Matilda, Lunt, Mark, de Roock, Sytze, Ruperto, Nicolino, Schoemaker, Casper, Vijatov-Djuric, Gordana, Vojinovic, Jelena, Vougiouka, Olga, Wulffraat, Nico M, Hyrich, Kimme L, Minden, Kirsten, Swart, Joost F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157174/ https://www.ncbi.nlm.nih.gov/pubmed/34613385 http://dx.doi.org/10.1093/rheumatology/keab641

Ejemplares similares

Development and External Validation of a Model Predicting New‐Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry
por: van Straalen, Joeri W., et al.
Publicado: (2023)

P66 Adalimumab originator versus biosimilar in children and young people with JIA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2022)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities
por: Beukelman, Timothy, et al.
Publicado: (2017)

Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016)

Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
por: Davies, Rebecca, et al.
Publicado: (2015)

Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2023)

A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2020)

The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data
por: Davies, Rebecca, et al.
Publicado: (2020)

What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
por: Swart, Joost F, et al.
Publicado: (2013)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

IL-18 production upon s100 stimulation is reduced in active sJIA patients compared to sJIA patients in remission and healthy controls
por: Haar, Nienke Ter, et al.
Publicado: (2014)

The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Susic, Gordana, et al.
Publicado: (2018)

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
por: van Straalen, Joeri W, et al.
Publicado: (2021)

Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany
por: Heiligenhaus, Arnd, et al.
Publicado: (2020)

Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis
por: Kihara, Mari, et al.
Publicado: (2016)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Long-term persistence with rituximab in patients with rheumatoid arthritis
por: Oldroyd, Alexander G S, et al.
Publicado: (2018)

OA35 Continuing specialist care into adulthood in young people with juvenile idiopathic arthritis: a retrospective cohort study using electronic health records in England
por: Costello, Ruth, et al.
Publicado: (2022)

Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline
por: Ganeva, Margarita, et al.
Publicado: (2021)

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis
por: Swart, Joost F, et al.
Publicado: (2018)

Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016)

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2016)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
por: de Roock, Sytze, et al.
Publicado: (2011)

P57 What are the outcomes of persistent oligoarthritis? A systematic review plan
por: Smith, Andrew, et al.
Publicado: (2022)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2018)

The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
por: Lawson-Tovey, Saskia, et al.
Publicado: (2023)

Outcome of adult patients with JIA treated with the biosimilar Benepali(®): results of the biologic register JuMBO
por: Vollbach, Kristina, et al.
Publicado: (2022)

Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review
por: Horneff, Gerd, et al.
Publicado: (2023)

Continuing specialist care into adulthood in young people with juvenile idiopathic arthritis: a retrospective cohort study using electronic health records in England
por: Costello, Ruth E, et al.
Publicado: (2022)

Not all moderate disease is the same – Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity
por: Pan, Yi, et al.
Publicado: (2019)

Correction: Not all moderate disease is the same – Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity
por: Pan, Yi, et al.
Publicado: (2020)

Authors reply to the ‘Response to “Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany”’
por: Heiligenhaus, Arnd, et al.
Publicado: (2023)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

How common is remission in juvenile idiopathic arthritis: A systematic review
por: Shoop-Worrall, Stephanie J.W., et al.
Publicado: (2017)

Prevalence of autoantibodies in patients with juvenile idiopathic arthritis: results from the German inception cohort ICON-JIA
por: Schulz, Caroline, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8356ugn7vgrhbdmt7fkre7vkbr